Skip to main content

BP Directors, LP's Form 4 filing

Actuate Therapeutics, Inc. (ACTU) · filed Aug 14, 2024

Accession no.
0001104659-24-089825
Filed
Aug 14, 2024, 8:54 PM ET
Trade date
Aug 12-14, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 30 non-derivative transactions and 26 derivative transactions. Open-market purchases total $4.00M. Open-market sales total $225.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
BP Directors, LPCIK 0001813311Director, 10% Owner
Bios Clinical Opportunity Fund, LPCIK 0001988639Director, 10% Owner
Bios Equity COF, LPCIK 0002000747Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 14, 2024Common StockCConversionAcquired+884,427–F1–884,427IndirectDuplicate filing
Aug 14, 2024Common StockPPurchaseAcquired+375,000$8.00+$3,000,0001,259,427IndirectDuplicate filing
Aug 14, 2024Common StockPPurchaseAcquired+125,000$8.00+$1,000,000125,000IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+525,797–F5–525,797IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+307,538–F5–307,538IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+141,457–F6–141,457IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+462,073–F6–462,073IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+61,857–F6–61,857IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+153,702–F6–153,702IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+54,032–F7–195,489IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+176,499–F7–638,572IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+23,628–F7–85,485IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+147,047–F7–300,749IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+101,900–F8–297,389IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+332,867–F8–971,439IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+44,559–F8–130,044IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+309,589–F9–309,589IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+2,022,029–F9–2,022,029IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+326,547–F9–326,547IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+2,094,650–F9–2,094,650IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+74,202–F10–383,791IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+484,638–F10–2,506,667IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+78,267–F10–404,814IndirectDuplicate filing
Aug 14, 2024Common StockCConversionAcquired+573,394–F10–573,394IndirectDuplicate filing
Aug 14, 2024Common StockXIn-the-money exerciseAcquired+8,068$5.27+$42,518.36305,457IndirectDuplicate filing
Aug 14, 2024Common StockSSaleDisposed−5,314$9.00−$47,826300,143IndirectDuplicate filing
Aug 14, 2024Common StockXIn-the-money exerciseAcquired+26,355$5.27+$138,890.85997,794IndirectDuplicate filing
Aug 14, 2024Common StockSSaleDisposed−17,361$9.00−$156,249980,433IndirectDuplicate filing
Aug 14, 2024Common StockXIn-the-money exerciseAcquired+3,528$5.27+$18,592.56133,572IndirectDuplicate filing
Aug 14, 2024Common StockSSaleDisposed−2,324$9.00−$20,916131,248IndirectDuplicate filing

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 14, 2024Common StockCConversionDisposed−884,427–F1–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−525,797–F5–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−307,538–F5–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−141,457–F6–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−462,073–F6–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−61,857–F6–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−153,702–F6–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−54,032–F7–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−176,499–F7–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−23,628–F7–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−147,047–F7–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−101,900–F8–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−332,867–F8–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−44,559–F8–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−309,589–F9–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−2,022,029–F9–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−326,547–F9–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−2,094,650–F9–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−74,202–F10–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−484,638–F10–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−78,267–F10–0IndirectDuplicate filing
Aug 14, 2024Common StockCConversionDisposed−573,394–F10–0IndirectDuplicate filing
Aug 14, 2024Common StockXIn-the-money exerciseDisposed−8,068$0.00$00IndirectDuplicate filing
Aug 14, 2024Common StockXIn-the-money exerciseDisposed−26,355$0.00$00IndirectDuplicate filing
Aug 14, 2024Common StockXIn-the-money exerciseDisposed−3,528$0.00$00IndirectDuplicate filing
Aug 12, 2024Common StockAGrant or awardAcquired+15,000$0.00$015,000IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to the initial offering price multiplied by 0.8.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

F5

Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date.

Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.

F6

Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date.

Referenced by the price of 4 transactions in Table I and 4 transactions in Table II.

F7

Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date.

Referenced by the price of 4 transactions in Table I and 4 transactions in Table II.

F8

Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date.

Referenced by the price of 3 transactions in Table I and 3 transactions in Table II.

F9

Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date.

Referenced by the price of 4 transactions in Table I and 4 transactions in Table II.

F10

Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date.

Referenced by the price of 4 transactions in Table I and 4 transactions in Table II.

Remarks

This Form 4 is the fifth of six Forms 4 filed relating to the same event. The Form 4 has been split into six filings because there are more than 10 reporting persons and 30 rows in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons and 30 rows. The first and second Forms 4 were filed by Leslie W. Kreis as the designated filer. The third and fourth Forms 4 were filed by Aaron G.L. Fletcher. The sixth Form 4 was filed by Bios Equity COF, LP as the designated filer. Each of the reporting persons other than Leslie W. Kreis may be deemed a "director by deputization" as the result of Aaron G.L. Fletcher's position as a director of the Issuer.

Read the full filing on SEC EDGAR (opens in a new tab)